Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 2,412 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Occlusive Vascular Disease Clear all
Terminated Phase 2 Interventional

Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy

NCT00742612
View directory record Official record
Conditions
Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
Interventions
ARC1779 Injection, Placebo (normal saline)
Drug
Lead sponsor
Archemix Corp.
Industry
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
2
States / cities
Hackensack, New Jersey • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2010 · Synced Oct 14, 2026, 7:24 PM EDT
Withdrawn Not applicable Interventional

Notify 2: An Evaluation of the Impact of Notification of Incidental Coronary Artery Calcium on Statin Rates

NCT05394181
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Notification
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Anti-inflammatory Effects of Simvastatin

NCT04638400
View directory record Official record
Conditions
Inflammation, Atherosclerosis, Hypercholesterolemia
Interventions
Simvastatin 40mg, Ezetimibe 10mg
Drug
Lead sponsor
paresh Dandona
Other
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

NCT03270514
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenoses, Valve Regurgitation, Mitral, Valve Regurgitation, Tricuspid
Interventions
Exparel Injectable Product, Bupivacaine Hydrochloride
Drug
Lead sponsor
Kathirvel Subramaniam
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of [3H] BMS747158 in Healthy Male Subjects

NCT00930631
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
[3H] BMS747158
Drug
Lead sponsor
Lantheus Medical Imaging
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 10, 2020 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

Rilonacept to Improve Artery Function in Patients With Atherosclerosis

NCT00417417
View directory record Official record
Conditions
Coronary Artery Disease, Atherosclerosis, Inflammation, Endothelial Dysfunction
Interventions
Rilonacept, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 30, 2012 · Synced Oct 14, 2026, 7:24 PM EDT
Not yet recruiting No phase listed Observational

A First-in-Human Feasibility Study of the Vibrant Stroke Detection Technology During Carotid Endarterectomies

NCT07851389
View directory record Official record
Conditions
Carotid Stenosis
Interventions
Bilateral carotid Doppler signal acquisition (Vibrant Stroke Detection Technology)
Device
Lead sponsor
Vibrant Medical Ltd.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Using Ultrasound Elastography to Predict Development of Hepatic Sinusoidal Obstruction Syndrome

NCT03865589
View directory record Official record
Conditions
Bone Marrow Transplant Complications, Sinusoidal Obstruction Syndrome, Veno Occlusive Disease, Hepatic, Stem Cell Transplant Complications
Interventions
Ultrasound Elastography
Diagnostic Test
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
1 Month to 99 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
7
States / cities
San Francisco, California • Boston, Massachusetts • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Completed No phase listed Observational

Magnetic Resonance Imaging (MRI) Viability: Comparison of Myocardial Viability by Positron Emission Tomography and MRI

NCT00166179
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years to 95 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 26, 2014 · Synced Oct 14, 2026, 7:24 PM EDT
Terminated Not applicable Interventional

Diamondback in Peripheral Vascular Disease

NCT03455374
View directory record Official record
Conditions
Peripheral Vascular Diseases, Critical Limb Ischemia
Interventions
Treatment with CSI atherectomy device
Device
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 14, 2026, 7:24 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

The Genetic, Protein, and Lipid Basis of Variation in Cholesterol Efflux

NCT04061018
View directory record Official record
Conditions
Lipid Metabolism Disorders
Interventions
Not listed
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 89 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Enrolling by invitation No phase listed Observational Accepts healthy volunteers

Multimodal Physiologic State Intelligence Study

NCT07814118
View directory record Official record
Conditions
Heart Failure, Cardiomyopathies, Pulmonary Hypertension, Myocarditis; Acute or Subacute, Myocarditis Due to Drug, Myocarditis Viral, Pericardial Diseases, Valvular Heart Diseases, Hypertension, Sepsis, Acute Kidney Injury, Pulmonary Edema - Acute, Pulmonary Edema With Heart Failure, Pulmonary Edemas, Acute Respiratory Distress Syndrome, Pulmonary Embolism Acute, Pulmonary Embolism (Diagnosis), Pulmonary Embolism Acute Massive, Pulmonary Embolism Subacute Massive, Venous Thrombosis Pulmonary, Venous Thrombosis (Disorder), Venous Thrombosis, Deep, Peripheral Arterial Disease, Peripheral Arterial Disease (PAD), Aortic Diseases, Muskuloskeletal Diseases, Brain Aging, Brain Aneurysm, Brain Aging Related Conditions, Ultrasound, Ultrasound Exams, Ultrasound Guidance
Interventions
OMNIPHYS Multimodal Ultrasound Imaging System
Device
Lead sponsor
Truway Health, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2046
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 4 Interventional Results available

Sugammadex Titration in Cardiac Surgery Patients

NCT05246397
View directory record Official record
Conditions
Coronary Artery Disease, Valvular Heart Disease, Aorta Disease, Heart Failure
Interventions
Sugammadex administration
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 21, 2024 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Not applicable Interventional

SHOWME-PAD (Peripheral Artery Disease)

NCT03190382
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
Decision Support Tool
Other
Lead sponsor
Saint Luke's Health System
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 14, 2026, 7:24 PM EDT
Recruiting Not applicable Interventional

Aggressive Lipid Lowering Therapy in ICI-Treated Melanoma

NCT07704918
View directory record Official record
Conditions
Melanoma
Interventions
Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
55 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 7, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 2 Interventional Results available

ACP-01 in Patients With Critical Limb Ischemia

NCT02551679
View directory record Official record
Conditions
Critical Limb Ischemia
Interventions
ACP-01, Placebo
Biological
Lead sponsor
Hemostemix
Industry
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
16
States / cities
Sacramento, California • Aurora, Colorado • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 14, 2026, 7:24 PM EDT
Terminated Phase 3 Interventional Results available

Niacin Plus Statin to Prevent Vascular Events

NCT00120289
View directory record Official record
Conditions
Cardiovascular Diseases, Heart Diseases, Cerebrovascular Accident, Coronary Disease, Atherosclerosis, Myocardial Infarction
Interventions
Extended release niacin, Simvastatin
Drug
Lead sponsor
Axio Research. LLC
Industry
Eligibility
45 Years and older
Enrollment
3,414 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
68
States / cities
Birmingham, Alabama • Hoover, Alabama • Pheonix, Arizona + 52 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 2 Interventional

Posterior Vitreous Detachment (PVD) Assessment During Dual Retinal Vein Occlusion (RVO) Lucentis Evaluations

NCT00831350
View directory record Official record
Conditions
Retinal Vein Occlusion, Posterior Vitreous Detachment
Interventions
Ranibizumab
Drug
Lead sponsor
Barnes Retina Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2017 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Phase 1 Interventional

Combination Stem Cell (MESENDO) Therapy for Utilization and Rescue of Infarcted Myocardium

NCT00548613
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Arteriosclerosis, Coronary Atherosclerosis, Coronary Disease
Interventions
MESENDO
Biological
Lead sponsor
TCA Cellular Therapy
Industry
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Covington, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 28, 2011 · Synced Oct 14, 2026, 7:24 PM EDT
Not listed Phase 3 Interventional

Myocardial Perfusion Assessment With Multidetector Computed Tomography

NCT00846079
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Regadenoson (Lexiscan) [muti-detector computed tomography]
Device
Lead sponsor
Tennessee Heart and Vascular Institute, P.C.
Other
Eligibility
18 Years to 80 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Hendersonville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 18, 2009 · Synced Oct 14, 2026, 7:24 PM EDT
Completed Not applicable Interventional

Pantheris Atherectomy Treatment of In-Stent Restenosis In Lower Extremity Arteries

NCT03192696
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Atherectomy Catheter
Device
Lead sponsor
Avinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
12
States / cities
Jonesboro, Arkansas • Little Rock, Arkansas • San Diego, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2023 · Synced Oct 14, 2026, 7:24 PM EDT
Withdrawn Phase 1 Interventional

Safety/ Feasibility of Percutaneous Administration of Vonapanitase as Monotherapy for Peripheral Artery Disease (PAD) of the SFA and Popliteal Arteries

NCT02953496
View directory record Official record
Conditions
Peripheral Artery Disease
Interventions
vonapanitase
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2019
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced Oct 14, 2026, 7:24 PM EDT
Active, not recruiting Phase 3 Interventional

A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque

NCT06305559
View directory record Official record
Conditions
Lipidemia, Coronary Artery Disease, Plaque, Atherosclerotic
Interventions
obicetrapib 10 mg + ezetimibe 10 mg FDC daily, Placebo
Drug · Other
Lead sponsor
NewAmsterdam Pharma
Industry
Eligibility
45 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Oct 14, 2026, 7:24 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Effects of Age and Exercise on Blood Pressure Regulation

NCT00319397
View directory record Official record
Conditions
Cardiovascular Disease, Aging
Interventions
Exercise-Training Program
Behavioral
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
55 Years to 75 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Oct 14, 2026, 7:24 PM EDT